Pyridoxal kinase, an enzyme involved in the conversion of vitamin B6 to its bioactive form, has been identified as a biomarker for predicting disease outcome in patients with non-small cell lung cancer (NSCLC). The researchers targeted the enzyme after performing a genome-wide screen that uncovered 85 factors including the pathways involved in vitamin B6 metabolism. Used as a way to stratify patient populations, pyridoxal kinase may indicate which patients would benefit from cisplantin and vitamin B6 therapy.